Hogan Lovells Advises AI Company in Achieving FDA Approval

IDx LLC, with assistance from Hogan Lovells, achieved a major grant of De Novo classification from the U.S. Food and Drug Administration for the novel artificial intelligence-based device IDx-DR. The product is the first device authorized for marketing that detects disease without the need for a clinician to also interpret the image or results, which makes it usable by health care providers who may not normally be involved in eye care.

External News Article: 
Add reference to external site news article
News Category: 
Member News